Brind.

Arcus Biosciences received Orphan Drug Designation from the U.S. FDA on July 10, 2025.

1 report, 1 independent Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Arcus Biosciences received Orphan Drug Designation from the U.S. FDA on July 10, 2025.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireArcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line t